The 1st International Online Conference on Personalized Medicine
The 1st International Online Conference on Personalized Medicine
Event's Timezone: Central European Time
1 July 2025
29 August 2025
24 October 2025
Personalized Medicine, Personalized Preventive Medicine, Pharmacogenetics Omics and Informatics, Precision Oncology, Disease Mechanisms Personalized, Personalized Therapy, Personalized Diagnostics
Welcome from the Chair
S2. Personalized Preventive Medicine;
S3. Diagnostics in Personalized Medicine;
S4. Personalized Therapy in Clinical Medicine;
S5. Pharmacogenetics, Omics, and Informatics;
S6. Precision Oncology
IOCPM 2025 will enable you to share and discuss your most recent research findings in Personalized Medicine with the vibrant global community of scientists and physicians in the field.
Prof. Dr. Kenneth P. H. Pritzker
MD, FRCPC
Professor Emeritus,
Laboratory Medicine and Pathobiology;
Surgery Temerty Faculty of Medicine,
University of Toronto, Toronto, Canada
Event Chairs
Laboratory Medicine and Pathobiology; Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Session chairs
Dr. Seungil Ro
Department of Physiology & Cell Biology, University of Nevada, Reno, School of Medicine, Nevada, USA
S1. Mechanisms of Diseases
diabetes; gastrointestinal disorders; smooth muscle; microRNAs; non-coding RNA
Dr. Seungil Ro has published 75 articles, including in several high-impact journals, on genetic and epigenetic regulation in diabetes, gastrointestinal disorders, and cancers. He holds seven U.S. and international patents for treatments targeting diabetes and gastrointestinal dysmotility and has secured over $12 million in research funding. As the founder of RosVivo Therapeutics, Dr. Ro has pioneered the development of therapeutic microRNAs for diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility. He has delivered over 80 presentations at international and domestic institutions, served as a panel reviewer for NIH and international grant programs, and contributed as an editor for multiple peer-reviewed journals.
Dr. Latha Palaniappan
Stanford Concierge and Executive Medicine, Stanford University, California, USA
S2. Personalized Preventive Medicine
Pharmacogenomics (PgX); Implementation Science; Racial/Ethnic Minorities; Chronic Disease and Prevention; Cardiovascular Disease; Diabetes
Latha Palaniappan MD, MS, is an internist, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention, and seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities. She was awarded a Stanford Impact Labs Leave in Service to pursue chronic disease prevention in India for Social Good. She is the Faculty co-Director of Stanford Biobank, designed to accelerate translatable scientific discoveries and co-founder for the Stanford Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE). CARE has established health related research collaborations in Asia, including student exchange programs in Hong Kong and Vietnam, and research collaborations in India, Japan, and Singapore. She has recently received a Fulbright Future Scholar Award and worked with the Commonwealth Scientific and Industrial Research Organization on implementation of Precision Health in Australia.
Dr. Kenneth Pritzker
Laboratory Medicine and Pathobiology; Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
S3. Diagnostics in Personalized Medicine
Personalized Medicine; Laboratory diagnostics; Arthritis; Biomineralization
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Dr. Taulant Muka
Epistudia, Bern, Switzerland
S4. Personalized Therapy in Clinical Medicine
evidence-based medicine; evidence synthesis; systematic reviews and meta-analyses; cardiometabolic health; sex differences in medicine; iron and estrogen; epidemiology; research methodology; healthcare Innovation; health disparities
Dr. Taulant Muka is among the top 2% of the world’s most influential scientists, with over 180 peer-reviewed publications and extensive expertise in evidence-based medicine and public health. As CEO of Epistudia, he pioneers education innovation through AI and e-learning tools. Dr. Muka's academic journey spans prestigious institutions like University of Bern, Erasmus, Cambridge, Harvard, and Stanford, with research focusing on cardiometabolic health, sex differences, and evidence synthesis. His work has been featured in global media outlets like BBC, CNN, and The New York Times.
Prof. Enrico Mini
Emeritus Professor of Medical Oncology, Department of Health Sciences, University of Florence, Florence, Italy
Pharmacogenetics, Omics, and Informatics
Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism
Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance. Prof. Mini is the author of more than 190 original articles in international peer reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses. In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London). Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology
Dr. Masakazu Kamata
Department of Microbiology, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA
S6. Precision Oncology
Cancer immunotherapy, HIV immunotherapy, CAR-T, CAR-Mac, bidirectional antibody, immunomodulator
Our research team is focused on creating a clinically relevant animal model to enhance our understanding of biology and develop new therapies for metastatic cancer and HIV-infected cells. Each model aims to investigate the complex mechanisms of cancer or HIV biology and their treatment effects at the molecular scale. Uncovering specific pathways has led to the emergence of new pharmaceuticals, such as antibody-drug conjugates, immunomodulators, and chimeric antigen receptors.
Event Committee
Centre for Health Technology, Faculty of Health, University of Plymouth, United Kingdom
Dr. Shang-Ming Zhou is a distinguished Professor of eHealth at the University of Plymouth, UK, where he serves as the Deputy Director of the Centre for Health Technology in the Faculty of Health: Medicine, Dentistry and Human Sciences. Dr. Zhou's work focuses on AI-driven personalized medicine, health informatics, health data science, disease phenotyping, risk stratification, polypharmacy, multimorbidity, and public health research. He leads different projects, advancing healthcare data analytics for patient-centric innovations.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy,
Scleroderma Unit, Division of Rheumatology, AO Careggi Hospital, Florence, Italy
Silvia Bellando Randone is an Associate Professor at the University of Florence’s Department of Experimental and Clinical Medicine. She specializes in Rheumatology, with clinical expertise in systemic sclerosis, rheumatoid arthritis, spondyloarthritis, myositis, and Sjögren’s syndrome, focusing on early diagnosis and personalized treatments. She leads the Scleroderma Unit at Careggi University Hospital. Her research focuses on the early diagnosis of rheumatic diseases, particularly systemic sclerosis, exploring the microbiota’s role in disease pathogenesis and identifying biomarkers for disease progression and treatment response.She is a member of national and international research organizations like SIR, EUSTAR, and GRAPPA. Dr. Bellando Randone teaches in various programs at the University of Florence and serves on the PhD Faculty Board in Clinical Sciences. She has authored over 160 scientific papers and regularly speaks and moderates at national and international rheumatology congresses
Personalised Medicine Centre, School of Medicine, Ulster University, Coleraine, United Kingdom
Dr Duddy is Senior Lecturer in Stratified Medicine (Bioinformatics) at the Personalised Medicine Centre in Ulster University’s School of Medicine. As co-lead of the neuromuscular research team, he builds on a diverse background in molecular & cellular biology, biochemistry, and bioinformatics, to integrate systems biology data analytics into the team’s cell and molecular studies. This integrative approach has led the team to investigate the role of secretory vesicles in neuromuscular and neurodegenerative disorders, and to their identification of vesicles as a source of neuronal toxicity. Dr Duddy’s commitment to neuromuscular research and wider interest in Personalised Medicine derive from losing his brother to Duchenne muscular dystrophy.
Registration
The registration for IOCPM 2025 will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 24 October 2025.
Instructions for Authors
IOCPM 2025 will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
Deadline for abstract acceptance notification: 29 August 2025. You will be notified of the acceptance of an oral presentation in a separate email.
1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
3. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
4. The abstracts submitted to this conference must be original and novel, without prior publication in any journals or it will not be accepted to this conference.
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session. Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the abstract. Slides, if available, will be displayed directly on the website using the proprietary slide viewer at Sciforum.net.
- Size in pixel: 1080 width x 1536 height–portrait orientation.
- Size in cm: 38,1 width x 54,2 height–portrait orientation.
- Font size: ≥16.
- Examples of successful submissions can be viewed here at the following links: (1), (2), (3)
- You can use our free template to create your poster. The poster template can be downloaded HERE.
It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunity
Participants in this conference are cordially invited to contribute a full manuscript to a Special Issue published in Journal of Personalized Medicine (ISSN: 2075-4426), with a 20% discount on the publication fee. Please note if you have IOAP/association discounts, conference discounts will be combined with IOAP/association discounts. Conference discounts cannot be combined with reviewer vouchers or any other vouchers. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
All accepted abstracts will be published in the conference report of IOCPM2025 in Medical Sciences Forum (ISSN: 2673-9992) after quality check. If you wish to publish an extended proceeding paper (4-8 pages), please submit it to the same journal after the conference.
Title
Full author names
Affiliations (including full postal address) and authors' e-mail addresses
Abstract
Keywords
Introduction
Methods
Results and Discussion
Conclusions
Acknowledgments
Event Awards
The Awards
Number of Awards Available: 4
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
